Internship

Summer Intern PhD Student

Materials Characterization/Process Analytical Technologies

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Franklin Township, NJ, USA

Interns residing more than 50 miles away may be eligible for a travel or housing stipend.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis
Requirements
  • Candidates must be currently enrolled in an accredited university program seeking a Ph.D. in Analytical Chemistry, Physical Chemistry, Materials Science, Pharmaceutical Sciences, Physics, or a related field, with a focus on Materials Characterization or PAT. Candidate must still be enrolled during Summer 2025.
  • Must include GPA on resume; program requires GPA of 3.0 or greater.
  • Expertise related to powders, crystallography, powder flow, particle size analysis, and/or with tools such as spectroscopy, chemometrics, or related techniques for process optimization and monitoring.
  • Additional familiarity with chemometrics is a plus.
  • Excellent critical thinking skills and the ability to work independently and as part of a team.
  • Effective communication and people skills.
  • Proficiency in data analysis software and tools.
Responsibilities
  • Develop methods for product characterization.
  • Develop and implement PAT methods to monitor and control pharmaceutical processes.
  • Design and execute experiments to evaluate PAT tools and develop and validate methods.
  • Collaborate with multi-disciplinary teams, including formulation scientists, analytical chemists, process engineers, and process modelers, to enable drug product formulation development and manufacturing processes.
  • Troubleshoot and resolve issues related to characterization and PAT methodologies.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and cardiovascular conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with AI Proteins could lead to significant revenue from miniprotein-based therapeutics.
  • FDA approval of Opdivo enhances BMS's leadership in lung cancer treatment.
  • Introduction of Cobenfy positions BMS to capture the psychiatric drug market.

What critics are saying

  • Legal challenges with the 340B Program may affect BMS's pricing strategies.
  • The $6.4 billion lawsuit by UMB could result in financial liabilities.
  • High R&D costs in collaborations like AI Proteins pose risks of unsuccessful outcomes.

What makes Bristol-Myers Squibb unique

  • BMS focuses on innovative treatments in oncology, immunology, and cardiovascular diseases.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?